Notice2024-03121
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
February 15, 2024
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 32 (Thursday, February 15, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 32 (Thursday, February 15, 2024)]
[Notices]
[Page 11845]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-03121]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained
by communicating with the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852 by contacting Dawn Taylor-Mulneix at
301-451-8021 or <a href="/cdn-cgi/l/email-protection#b2d6d3c5dc9cc6d3cbdeddc09fdfc7dedcd7dbcaf2dcdbda9cd5ddc4"><span class="__cf_email__" data-cfemail="711510061f5f0510081d1e035c1c041d1f141809311f18195f161e07">[email protected]</span></a>. A signed Confidential
Disclosure Agreement will be required to receive copies of unpublished
information related to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows:
Equipping Natural Killer Cells With a CD28H-Containing Chimeric Antigen
Receptor To Overcome Inhibition for Cancer Immunotherapy
Description of Technology
Immunotherapy with chimeric antigen receptor (CAR) cytotoxic T
cells have been successful in the clinical treatment of hematologic
cancers; however adverse side effects such as severe cytokine release
syndrome and neurotoxicity are associated with CAR-T cell infusion. CAR
natural killer (NK) cells represent a viable alternative with
demonstrated advantages over CAR-T cells for the elimination of tumor
cells, but NK inhibitory cell receptors need to be reduced or
overridden. To overcome this challenge, scientists at NIAID have
developed CAR constructs that overcome inhibition of NK cells by
receptors for human major histocompatibility complex molecules HLA-E
and HLA-C, based on in vitro studies. NK cells that are expressing
variants of this invention robustly overcome inhibition imposed by
CD19\+\ HLA-I\+\ tumor cells and are cytotoxic to them.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications
<bullet> Method of adoptive cell therapy where CAR-NK cells are the
effective cell.
Competitive Advantages
<bullet> CD28H CAR-NK cells induce a more robust anti-tumor
cytotoxic activity compared to third generation CAR-T cells and are
more potent in overcoming inhibition.
<bullet> CAR-NK can be developed without the need of genetic
silencing of TCR.
Developmental Stage
<bullet> Pre-clinical.
Inventors: Eric Long, Ph.D. and Xiaoxuan Zhuang, both of NIAID.
Publications:
Zhuang X., Long E.O., ``NK cells equipped with a chimeric antigen
receptor that overcomes inhibition by HLA Class I for adoptive transfer
of CAR-NK Cells. Front. Immunol. 13:840844. <a href="https://www.frontiersin.org/articles/10.3389/fimmu.2022.840844/full">https://www.frontiersin.org/articles/10.3389/fimmu.2022.840844/full</a>. May 2,
2022.
Zhuang X. and Long E.O., ``CD28 homolog is a strong activator of
Natural Killer cells for lysis of B7H7-positive tumor cells.'' Cancer
Immunol. Res. 7(6):939-951. <a href="https://cancerimmunolres.aacrjournals.org/content/7/6/939.long">https://cancerimmunolres.aacrjournals.org/content/7/6/939.long</a>. April 24, 2019.
Zhuang X, Long E.O. ``Inhibition-resistant CARs for NK cell cancer
immunotherapy.'' Trends Immunol. 40(12):1078-1081.https://
<a href="http://www.sciencedirect.com/science/article/pii/S1471490619302133?via%3Dihub">www.sciencedirect.com/science/article/pii/S1471490619302133?via%3Dihub</a>.
November 12, 2019.
Intellectual Property: HHS Reference No. E-097-2020; Patent
Application Nos.: PCT Application No. PCT/US2020/02498, US: 17/914,027,
Australia: 2020437669, Brazil: BR112022017512-4, Canada: 3174779,
Europe: 20719313.7, India: 2022170585054, Japan: 2022-557764, South
Korea: 10-2022-7037236.
Licensing Contact: To license this technology, please contact Dawn
Taylor-Mulneix at 301-451-8021 or <a href="/cdn-cgi/l/email-protection#046065736a2a70657d686b76296971686a616d7c446a6d6c2a636b72"><span class="__cf_email__" data-cfemail="afcbced8c181dbced6c3c0dd82c2dac3c1cac6d7efc1c6c781c8c0d9">[email protected]</span></a>, and
reference E-097-2020.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize this technology. For collaboration
opportunities, please contact Dawn Taylor-Mulneix at 301-451-8021 or
<a href="/cdn-cgi/l/email-protection#8befeafce5a5ffeaf2e7e4f9a6e6fee7e5eee2f3cbe5e2e3a5ece4fd"><span class="__cf_email__" data-cfemail="432722342d6d37223a2f2c316e2e362f2d262a3b032d2a2b6d242c35">[email protected]</span></a>.
Dated: February 9, 2024.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2024-03121 Filed 2-14-24; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on February 15, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.